MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.55 3.88

Buy Sell

Overview

Share price change

24h

Current

Min

4.42

Max

4.65

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+77.35% upside

Market Stats
By TradingEconomics
Market Cap	-97M 2.3B
Previous open	0.67
Previous close	4.55

News Sentiment

By Acuity

50%

164 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 sty 2026, 21:14 UTC

Major Market Movers

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6 sty 2026, 19:23 UTC

Acquisitions, Mergers, Takeovers

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6 sty 2026, 17:41 UTC

Major Market Movers

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6 sty 2026, 15:46 UTC

Acquisitions, Mergers, Takeovers

Advent International Leads InPost Takeover Offer, Sky News Says

6 sty 2026, 15:37 UTC

Major Market Movers

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6 sty 2026, 23:46 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

6 sty 2026, 23:35 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6 sty 2026, 23:19 UTC

Market Talk

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6 sty 2026, 22:53 UTC

Market Talk

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6 sty 2026, 22:03 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6 sty 2026, 22:03 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 sty 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 sty 2026, 21:12 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 sty 2026, 21:12 UTC

Market Talk

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6 sty 2026, 20:59 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6 sty 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6 sty 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6 sty 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced Imminently, Sources Say -- WSJ

6 sty 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6 sty 2026, 20:01 UTC

Market Talk

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6 sty 2026, 19:52 UTC

Market Talk

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6 sty 2026, 19:46 UTC

Acquisitions, Mergers, Takeovers

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6 sty 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

OneStream to Go Private Through $6.4B Hg Acquisition

6 sty 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6 sty 2026, 17:20 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

6 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

6 sty 2026, 15:57 UTC

Market Talk

Crude Futures Ease Back From Early Gains -- Market Talk

6 sty 2026, 15:34 UTC

Market Talk

Earnings

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6 sty 2026, 15:27 UTC

Market Talk

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

77.35% upside

12 Months Forecast

Average 7.75 USD 77.35%

High 11 USD

Low 5 USD

Based on 6 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

164 / 373 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.